The Amsterdam Cohort Studies on HIV infection Annual Report 2006

Introduction The Amsterdam Cohort Studies (ACS) on HIV infection and AIDS were started shortly after the first cases of AIDS were diagnosed in the Netherlands. Since October 1984, men who have sex with men (MSM) have been enrolled in a prospective cohort study. A second cohort involving drug users (DU) was initiated in 1985. In 2013, the cohorts reached 29 years of follow-up. The initial aim of the ACS was to investigate the prevalence and incidence of HIV1 infection and AIDS and their risk factors, the natural history and pathogenesis of HIV-1 infection, and the effects of interventions. During the past 29 years, these aims have remained primarily the same, although the emphasis of the studies has changed. Early on, the primary focus was to elucidate the epidemiology of HIV-1 infection, whereas later more in-depth studies were performed to investigate the pathogenesis of HIV-1 infection. In recent years, the focus has shifted to also include the epidemiology and natural history of other blood-borne and sexually transmitted infections (STI) among the participants in the ACS.

[1]  G. Tjon.  Molecular epidemiology of Hepatitis A in the Netherlands , 2006 .

[2]  R. Geskus,et al.  Highly active antiretroviral therapy (HAART) among HIV-infected drug users: a prospective cohort study of sexual risk and injecting behaviour. , 2006, Addiction.

[3]  B. Berkhout,et al.  Opposing roles of blood myeloid and plasmacytoid dendritic cells in HIV-1 infection of T cells: transmission facilitation versus replication inhibition. , 2006, Blood.

[4]  H. Schuitemaker,et al.  Impact of CCR5 Δ32/+ Deletion on Herpes Zoster Among HIV-1-Infected Homosexual Men , 2006, European Journal of Epidemiology.

[5]  J. Goedert,et al.  Cohort- and time-specific associations of CTLA4 genotypes with HIV-1 disease progression , 2006, AIDS.

[6]  M. Prins,et al.  Decline in HIV incidence and injecting, but not in sexual risk behaviour, seen in drug users in Amsterdam: a 19-year prospective cohort study , 2006, AIDS.

[7]  N. Pantazis,et al.  Highly Active Antiretroviral Therapy Interruption: Predictors and Virological and Immunologic Consequences , 2006, Journal of acquired immune deficiency syndromes.

[8]  Kholoud Porter,et al.  Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion , 2006, AIDS.

[9]  G. Schippers,et al.  Motives for and Against Injecting Drug Use Among Young Adults in Amsterdam: Qualitative Findings and Considerations for Disease Prevention , 2006, Substance use & misuse.

[10]  J. Wit,et al.  Relationship Characteristics and Risk of HIV Infection: Rusbult's Investment Model and Sexual Risk Behavior of Gay Men in Steady Relationships1 , 2006 .

[11]  D. Pillay,et al.  Evolution of Transmitted HIV-1 with Drug-Resistance Mutations in the Absence of Therapy: Effects on Cd4+ T-Cell Count and HIV-1 Rna Load , 2006, Antiviral therapy.

[12]  H. Jacqmin-Gadda,et al.  Determinants of response to first HAART regimen in antiretroviral‐naïve patients with an estimated time since HIV seroconversion , 2006, HIV medicine.

[13]  W. Paxton,et al.  Bile Salt-Stimulated Lipase from Human Milk Binds DC-SIGN and Inhibits Human Immunodeficiency Virus Type 1 Transfer to CD4+ T Cells , 2006, Antimicrobial Agents and Chemotherapy.

[14]  M. Cornelissen,et al.  Absence of seroreversion in 80 HAART-treated HIV-1 seropositive patients with at least five-years undetectable plasma HIV-1 viral load , 2006, AIDS research and therapy.

[15]  E. Bunnik,et al.  Longer V1V2 Region with Increased Number of Potential N-Linked Glycosylation Sites in the HIV-1 Envelope Glycoprotein Protects against HIV-Specific Neutralizing Antibodies , 2011, Journal of Virology.

[16]  P. Jansen,et al.  Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project , 2011, European journal of gastroenterology & hepatology.

[17]  R. Wyatt,et al.  Immunization with Recombinant HLA Classes I and II, HIV-1 gp140, and SIV p27 Elicits Protection against Heterologous SHIV Infection in Rhesus Macaques , 2011, Journal of Virology.

[18]  H. Schuitemaker,et al.  Clinical significance of HIV-1 coreceptor usage , 2011, Journal of Translational Medicine.

[19]  M. Prins,et al.  Harm reduction intensity-Its role in HAART adherence amongst drug users in Amsterdam. , 2011, The International journal on drug policy.

[20]  H. Schuitemaker,et al.  Evolution of Human Immunodeficiency Virus Type 1 in a Patient with Cross-Reactive Neutralizing Activity in Serum , 2011, Journal of Virology.

[21]  B. Berkhout,et al.  Altered dynamics and differential infection profiles of lymphoid and myeloid cell subsets during acute and chronic HIV‐1 infection , 2011, Journal of leukocyte biology.

[22]  O. Delaneau,et al.  Screening Low-Frequency SNPS From Genome-Wide Association Study Reveals a New Risk Allele for Progression to AIDS , 2011, Journal of acquired immune deficiency syndromes.

[23]  W. Paxton,et al.  Sexual transmission of hepatitis C virus in human immunodeficiency virus-negative men who have sex with men: a series of case reports. , 2011, Sexually transmitted diseases.

[24]  H. Schuitemaker,et al.  Low incidence of HIV-1 superinfection even after episodes of unsafe sexual behavior of homosexual men in the Amsterdam Cohort Studies on HIV Infection and AIDS. , 2011, The Journal of infectious diseases.

[25]  E. Bunnik,et al.  Activity of Broadly Neutralizing Antibodies, Including PG9, PG16, and VRC01, against Recently Transmitted Subtype B HIV-1 Variants from Early and Late in the Epidemic , 2011, Journal of Virology.

[26]  H. Schuitemaker,et al.  Rising HIV-1 viral load set point at a population level coincides with a fading impact of host genetic factors on HIV-1 control , 2011, AIDS.

[27]  O. Delaneau,et al.  CD39/Adenosine Pathway Is Involved in AIDS Progression , 2011, PLoS pathogens.

[28]  D. van Baarle,et al.  Influence of HIV Infection on Cytomegalovirus-Specific Immunity: T-Cell Responses to Pp65 and Ie1 before and after Haart May Refect Altered Cytomegalovirus Biology , 2011, Antiviral therapy.

[29]  Philippe Lemey,et al.  Time-measured phylogenies of gag, pol and env sequence data reveal the direction and time interval of HIV-1 transmission , 2011, AIDS.

[30]  R. Geskus,et al.  Ongoing HIV-1 transmission among men who have sex with men in Amsterdam: a 25-year prospective cohort study , 2011, AIDS.

[31]  C. Sabin,et al.  Decline of CD4+ T-cell count before start of therapy and immunological response to treatment in antiretroviral-naive individuals , 2011, AIDS.

[32]  B. Grady,et al.  No impact of hepatitis C virus infection on mortality among drug users during the first decade after seroconversion. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[33]  Rick Quax,et al.  Increasing risk behaviour can outweigh the benefits of antiretroviral drug treatment on the HIV incidence among men-having-sex-with-men in Amsterdam , 2010, BMC infectious diseases.

[34]  O. Delaneau,et al.  Genome-Wide Association Scan in HIV-1-Infected Individuals Identifying Variants Influencing Disease Course , 2011, PloS one.

[35]  B. D. De Stavola,et al.  Immune reconstitution and risk of Kaposi sarcoma and non-Hodgkin lymphoma in HIV-infected adults , 2011, AIDS.

[36]  David Dunn,et al.  Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. , 2011, The Lancet. Infectious diseases.

[37]  R. Geskus,et al.  1175 THE HEPATITIS C EPIDEMIC AMONG HIV-POSITIVE MEN WHO HAVE SEX WITH MEN: INCIDENCE ESTIMATES FROM 1990 TO 2007 , 2011 .

[38]  N. Kootstra,et al.  Macrophages and HIV-1. , 2011, Current opinion in HIV and AIDS.

[39]  B. Berkhout,et al.  Loss of HIV-1-derived cytotoxic T lymphocyte epitopes restricted by protective HLA-B alleles during the HIV-1 epidemic , 2011, AIDS.

[40]  A. Mocroft,et al.  HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4⁺ T-cell lymphocytes. , 2011, Blood.

[41]  M. Suchard,et al.  Impact of CCR5delta32 host genetic background and disease progression on HIV-1 intrahost evolutionary processes: efficient hypothesis testing through hierarchical phylogenetic models. , 2011, Molecular biology and evolution.

[42]  E. Bunnik,et al.  Detection of Inferred CCR5- and CXCR4-Using HIV-1 Variants and Evolutionary Intermediates Using Ultra-Deep Pyrosequencing , 2011, PLoS pathogens.

[43]  E. Bunnik,et al.  Polymorphism in HIV-1 dependency factor PDE8A affects mRNA level and HIV-1 replication in primary macrophages. , 2011, Virology.

[44]  B. Grady,et al.  Female Sex and IL28B, a Synergism for Spontaneous Viral Clearance in Hepatitis C Virus (HCV) Seroconverters from a Community-Based Cohort , 2011, PloS one.

[45]  S. Cole,et al.  Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters. , 2011, Archives of internal medicine.

[46]  B. Berkhout,et al.  Protein X of Hepatitis B Virus: Origin and Structure Similarity with the Central Domain of DNA Glycosylase , 2011, PloS one.

[47]  H. Schuitemaker,et al.  Comparison of in vivo and in vitro evolution of CCR5 to CXCR4 coreceptor use of primary human immunodeficiency virus type 1 variants. , 2011, Virology.

[48]  M. Kretzschmar,et al.  Estimating the force of infection for HCV in injecting drug users using interval-censored data , 2011, Epidemiology and Infection.

[49]  I. Stolte,et al.  Serosorting and sexual risk behaviour according to different casual partnership types among MSM: the study of one-night stands and sex buddies , 2012, AIDS care.

[50]  C. Morrison,et al.  Risk of tuberculosis following HIV seroconversion in high-income countries , 2012, Thorax.

[51]  N. Haigwood,et al.  HIV-1 Envelope Glycoprotein Resistance to Monoclonal Antibody 2G12 Is Subject-Specific and Context-Dependent in Macaques and Humans , 2013, PloS one.

[52]  P. Lips,et al.  Low bone mineral density, regardless of HIV status, in men who have sex with men. , 2013, The Journal of infectious diseases.

[53]  I. Stolte,et al.  Undetectable Viral Load and the Decision to Engage in Unprotected Anal Intercourse Among HIV-Positive MSM , 2013, AIDS and Behavior.

[54]  H. D. de Melker,et al.  Seroepidemiology of High-Risk HPV in HIV-Negative and HIV-Infected MSM: The H2M Study , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[55]  Nienke van der Knaap,et al.  Druggebruikers in Amsteredam: lopen ze nog risico op hiv? , 2013 .

[56]  G. Lauer,et al.  COHORT PROFILE Cohort Profile : The International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts ( InC 3 ) Study , 2014 .

[57]  N. Nanlohy,et al.  Ongoing risk behavior and the presence of HCV-RNA affect the hepatitis C virus (HCV)-Specific CD4(+) T cell response. , 2013, Viral immunology.

[58]  H. Schuitemaker,et al.  Genome-Wide Association Study on the Development of Cross-Reactive Neutralizing Antibodies in HIV-1 Infected Individuals , 2013, PloS one.

[59]  C. Meijer,et al.  Anal and penile high-risk human papillomavirus prevalence in HIV-negative and HIV-infected MSM , 2013, AIDS.

[60]  C. Sabin,et al.  Natural history of HIV-control since seroconversion , 2013, AIDS.

[61]  M. Kretzschmar,et al.  Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction? , 2013, Addiction.

[62]  B. Grady,et al.  Hepatitis C virus reinfection following treatment among people who use drugs. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[63]  D. Pillay,et al.  Impact of HIV-1 subtype on CD4 count at HIV seroconversion, rate of decline, and viral load set point in European seroconverter cohorts. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[64]  Paul J. McLaren,et al.  Association Study of Common Genetic Variants and HIV-1 Acquisition in 6,300 Infected Cases and 7,200 Controls , 2013, PLoS pathogens.

[65]  The Presence of CXCR4-Using HIV-1 Prior to Start of Antiretroviral Therapy Is an Independent Predictor of Delayed Viral Suppression , 2013, PloS one.

[66]  B. Berkhout,et al.  High prevalence of hepatitis B virus dual infection with genotypes A and G in HIV-1 infected men in Amsterdam, the Netherlands, during 2000-2011 , 2013, BMC Infectious Diseases.

[67]  Jacques Fellay,et al.  Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[68]  J. Heringa,et al.  HIV-1 Replication Fitness of HLA-B*57/58:01 CTL Escape Variants Is Restored by the Accumulation of Compensatory Mutations in Gag , 2013, PloS one.

[69]  R. Geskus,et al.  Drug Users in Amsterdam: Are They Still at Risk for HIV? , 2013, PloS one.

[70]  Jaap Heringa,et al.  HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity , 2013, Retrovirology.

[71]  B. Berkhout,et al.  Translational HIV-1 research: from routine diagnostics to new virology insights in Amsterdam, the Netherlands during 1983-2013 , 2013, Retrovirology.

[72]  B. Grady,et al.  Identification of a new genotype of Torque Teno Mini virus , 2013, Virology Journal.

[73]  J. Hahn,et al.  Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[74]  I. Stolte,et al.  Is Serosorting Effective in Reducing the Risk of HIV Infection Among Men Who Have Sex With Men With Casual Sex Partners? , 2014, Journal of acquired immune deficiency syndromes.

[75]  G. Lauer,et al.  The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection , 2014, Hepatology.

[76]  I. Stolte,et al.  High awareness of hepatitis C virus (HCV) but limited knowledge of HCV complications among HIV-positive and HIV-negative men who have sex with men , 2014, AIDS care.